Monday, February 11, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY), ConocoPhillips (COP) and Qualcomm (QCOM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked Bristol-Myers ' shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past six months, -15.5% vs. +2.1%. Bristol-Myers topped fourth-quarter earnings on robust sales of Opdivo and Eliquis. Bristol-Myers' blockbuster immuno-oncology drug
The Zacks analyst thinks Opdivo's performance is being boosted by the uptake in new indications in the United States - first line RCC and adjuvant melanoma. Eliquis is expected to drive growth, owing to increases in market share in the novel oral anticoagulant market. The label expansion of other drugs like Sprycel and Empliciti should further boost sales.
The recently announced acquisition of Celgene should strengthen the oncology franchise. However, the company's voluntary withdrawal of the sBLA seeking approval of Opdivo+Yervoy as a treatment for first-line NSCLC with tumor mutational burden greater or equal to 10 mutations/megabase following discussions with the FDA was disappointing given the market potential.
(You can read the full research report on Bristol-Myers here >>> ).
Shares of ConocoPhillips are up 24% over the past year, outperforming the Zacks U.S. Integrated Oil industry, which has increased +0.1% over the same period. The Zacks analyst emphasizes that in terms of production and proved reserves, ConocoPhillips is the largest oil and gas exploration and production (E&P) player in the world.
Notably, there are significant opportunities for the upstream energy player in the Eagle Ford where it owns about 3,400 undrilled locations. In fact, strong focus on two other prospective resources like Delaware basin and Bakken shale is expected to help ConocoPhillips achieve its target of more than 25% CAGR of production through 2017 to 2019.
The company recently reported strong fourth-quarter 2018 earnings, thanks to robust volumes from the unconventional assets. However, the firm's projection of higher production and operating costs is likely to hurt its bottom line. Moreover, since majority of ConocoPhillips' production comprises oil, the volatile crude pricing scenario could hurt the company's operations.
(You can read the full research report on ConocoPhillips here >>> ).
Qualcomm 's shares have lost 23.4% over the past year, underperforming the Zacks Wireless Equipment industry, which has lost -5.4% over the same period. Qualcomm reported mixed first-quarter fiscal 2019 results wherein the bottom line beat expectations but the top line missed the same. The company expects improving conditions for its chip business in the second half of fiscal 2019 on the back of new product launches.
The Zacks analyst likes how the company continues to execute its strategic objectives, including driving the global transition to 5G, protecting its intellectual property rights and expanding into new industries and product categories to stoke growth. Qualcomm's Snapdragon 855 is gaining significant momentum with more than 100 design wins in development.
Aggressive competition in the mobile phone chipset market is likely to hurt profitability. Over the past quarters, Qualcomm's results were adversely impacted by ongoing legal disputes with Apple. It is also facing competitive threat from its closest rival, Intel.
(You can read the full research report on Qualcomm here >>> ).
Other noteworthy reports we are featuring today include T-Mobile (TMUS), General Motors (GM) and Marathon Petroleum (MPC).
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Label Expansion of Opdivo, Eliquis Fuel Bristol-Myers (BMY)
ConocoPhillips (COP) Banks on Bakken, Production Costs High
Qualcomm (QCOM) Rides on Portfolio Strength Amid Competition
Featured Reports
T-Mobile (TMUS) Defies Competition for Industry-Leading Growth
Per the Zacks analyst, T-Mobile remains poised to benefit from the industry-leading postpaid growth and record-low postpaid phone churn.
General Motors (GM) Rides on Strong Pricing of New Pickups
Per the Zacks analyst, General Motors rides on sturdy performance in North America, driven by strong pricing for its all-new full-size pickup trucks.
Marathon (MPC) Buoyed by Andeavor Buy Amid Low Crack Spread
While the successful integration of Andeavor's operations bode well for Marathon Petroleum, the Zacks analyst is worried over lower refining profitability due to narrowing crack spreads.
Emerson (EMR) Gains from Strong MRO Activities, Margins Weak
Per the analyst, strong performance of Emerson's Automation Solutions segment fuelled by strong brownfield projects & MRO activities should drive its revenues.
Trucks Drive Ford (F) Amid Waning Demand in China & Europe
Per the Zacks analyst, consistent rising demand for F-series trucks mainly in North America drives Ford's revenues.
Solid S.E.T Arm Aids Zimmer Biomet (ZBH) Amid Forex Woes
Per Zacks analyst, given focus on quality remediation, product launches and supply recovery efforts, Zimmer Biomet sees growth within S.E.T arm.
Improving Commissions and Fees Aid Willis Towers (WLTW)
Per the Zacks analyst, Willis Towers is set to grow on rising commissions and fees backed by organic growth across segments, which in turn drives higher revenues.
New Upgrades
Yum! Brands (YUM) Rides on Re-Franchising & Digital Efforts
The Zacks analyst thinks that Yum! Brands' shift to refranchising substantially helped the company's operating margin while digital innovation is likely to aid top line growth.
Cummins (CMI) Gains on Improved Demand, Innovative Products
Per the Zacks analyst, increased engine and component demand for truck production in North America and Europe drives Cummins' financials. Also, its innovative products and partnerships bode well.
Joint Venture, Domestic Projects Aid Buckeye Partners (BPL)
Per the Zacks analyst, Buckeye Partners focus to develop domestic assets through organic means and the joint venture to develop South Texas Gateway terminal will boost its performance.
New Downgrades
Lackluster Bank Spending, Competition Hurts Cognizant (CTSH)
Per the Zacks analyst, lackluster spending by big banks particularly in Asia-Pacific and stiff competition in the IT services market hurts Cognizant's growth.
Microchip (MCHP) Battered by Rising Lead Time & Debt Burden
Per the Zacks analyst, increasing lead time and significant exposure to Asian markets is anticipated to limit gross margin expansion. Further, highly leveraged balance sheet is a concern.
Consumer Beauty Division a Worry for Coty's (COTY) Top Line
Coty's Consumer Beauty unit has long been pressurized by supply chain woes, softness in mass beauty categories and competition. Per the Zacks analyst, recovery at this unit is likely to take time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
T-Mobile US, Inc. (TMUS): Free Stock Analysis Report
QUALCOMM Incorporated (QCOM): Free Stock Analysis Report
Marathon Petroleum Corporation (MPC): Free Stock Analysis Report
General Motors Company (GM): Free Stock Analysis Report
ConocoPhillips (COP): Get Free Report
Bristol-Myers Squibb Company (BMY): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
